RESEARCH & DEVELOPMENT
AXIM Biotechnologies’ research and development efforts are concentrated in the alternative energy, pharmaceutical/nutraceutical, phytoplant and botanical fields as well as investments in (and acquisitions of) innovative and prospective biotechnology entities.
We are continuing our research and development at the Free University of Amsterdam with our novel, patented delivery system for treatment of patients with pain and spasticity as a sequence of Multiple Sclerosis. This study will include also the University of Plymouth, UK and University Centers in the USA. The study is conducted in strict compliance with FDA/EMA guidelines and is supervised by QPS as a CRO. The product tested is a pharmaceutical, functional chewing gum containing equal parts of THC and CBD. With our proprietary technology, numerous problems related to the water insolubility of cannabinoids due to their lipophilic nature, bypass of first-pass liver metabolism and direct delivery into the systemic circulation have been resolved.
Clinical studies will commence at the University of Wageningen, The Netherlands, testing new delivery systems with novel cannabinoids for the treatment of patients with IBS, IBD, and Crohn’s disease. A new direct, as well as controlled slow-release nano-technology delivery method, will be investigated based on our proprietary IP.
New, patent-pending cannabinoid extraction techniques as well as pure, water-soluble, solid-state carriers with cannabinoids were developed in cooperation with Syncom, BV, The Netherlands, which practically solves the issue with formulation as well as very poor absorption of currently available, oil based cannabinoids.
There are numerous other R&D projects being considered involving our proprietary IP. These will be strategically planned depending on availability of funds to carry on.